In obesity, elevated levels of proinflammatory cytokines such as adiponectin, leptin, resistin, nitric oxide, interleukins, tumor necrosis factor (TNF), and other inflammatory mediators interact with systemic changes, including increased insulin resistance, RAAS activation, lipotoxicity, and interstitial fibrosis, contributing to CVD development in olanzapine‐treated patients. Here, INS is linked to obesity disorder.